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ABSTRACT
Vitamin D is a particularly important sterol hormone, with evidence emerging of its 
beneficial effects well beyond bone. In consequence of this and increased global 
recognition of vitamin D deficiency in the general population, there has been a resurgence 
in treatment with vitamin D preparations. However, the increasing use of vitamin D 
treatments has also seen a substantial increase in the number of reports of vitamin D 
intoxication, with the majority (75%) of reports published since 2010. Many of these cases 
are a consequence of inappropriate prescribing, and the use of highdose overthecounter 
preparations or unlicensed preparations. This review highlights that the majority of cases 
were preventable and discusses the inappropriate use of poorly formulated, and 
unlicensed vitamin D preparations.
INTRODUCTION
Vitamin D is somewhat of a misnomer as it is, in fact, a potent sterol hormone [1]. In 
consequence, there has been considerable research interest focused on this molecule 
over the past decade, particularly when compared with the relatively stable research 
output associated with other vitamins (Figures 1 and 2). The high prevalence of vitamin D 
deficiency is well recognized in Europe but is in fact a global problem, with female 
adolescents in the Middle East at particular risk [2-5]. This, and the beneficial effects of 
treatment on areas beyond bone [1], may have prompted the marked increase in the use 
of vitamin D therapies [6]. Similarly, populationbased guidelines [7] and advice from chief 
medical officers [8] have further supported the widespread use of vitamin D 
supplementation, with a recommended intake of 400 IU per day for those aged 4 years 
and above in the UK. However, vitamin D treatment is not without risk, as vitamin D toxicity 
is a potentially serious adverse effect of treatment. Vitamin D deficiency may also rise with 
increasing obesity rates as obesity is a key risk factor for vitamin D deficiency [9].
Vitamin D is synthesized mainly in the skin [1]; only 10% is derived from dietary sources. 
Cholecalciferol is synthesized from 7dehydrocholesterol via an enzymatic photosynthetic 
process involving ultraviolet radiation. This photosynthetic process is carefully regulated, 
such that balanced enzymatic degradation of cholecalciferol occurs within the skin, 
effectively preventing the accumulation of excess cholecalciferol [10]. Following the 
photosynthesis of cholecalciferol, the molecule undergoes 25hydroxylation in the liver to 
form 25hydroxycholecalciferol (25OHD) and then undergoes a further 1hydroxylation to 
form the active hormone, calcitriol, 1,25dihydroxycholecalciferol (1,25OHD) [1]. It is this 
molecule that is the active component of vitamin D, acting upon the widespread vitamin D 
receptors (VDRs) distributed ubiquitously throughout the body's organs. Through 
interaction with the VDRs, calcitriol exerts its main effects on calcium homeostasis, 
causing increased absorption of both calcium and phosphorus from the gut. Vitamin D 
deficiency is therefore associated with reduced calcium absorption and hence secondary 
hyperparathyroidism, resulting in recruitment of calcium from the bone in order to maintain 
adequate plasma calcium concentrations. Similarly, vitamin D toxicity is associated with 
increased absorption of calcium from the gut, and hypercalcaemia. Furthermore, vitamin D 
excess may increase bone resorption, further increasing calcium levels [11].
As vitamin D is mainly produced through photosynthesis, a multitude of factors influence 
levels, such as amount of sun exposure, time of day, season, latitude, altitude, cloud
cover, air pollution, clothing and sunscreen use. Current opinion suggests that vitamin D 
concentrations are best reflected through the measurement of 25OHD, although the 
definition of sufficiency differs between authorities as either a 25OHD concentration 
>50 nmol l–1 [12] or >75 nmol l–1 (Table 1) [13]. Thus, with public health advice increasingly 
recommending against prolonged sun exposure, the only way to restore adequate vitamin 
D concentrations is through supplemental vitamin D [7]. Either oral ergocalciferol (vitamin 
D2) or cholecalciferol (vitamin D3) is recommended, with the latter being more popular. 
Intramuscular preparations may be used, although this is rarely required, tending to be 
reserved for cases of malabsorption [12]. A popular approach to treating deficiency is via a 
total dose of 300 000 IU of either cholecalciferol or ergocalciferol, delivered as split doses 
over a 6–12week period, then followed by maintenance therapy of around 800–1000 IU 
daily [12].
Vitamin D toxicity
The features of vitamin D toxicity are mediated through hypercalcaemia, and symptoms 
range from mild, such as thirst and polyuria, to severe, including seizures, coma and death
[14]. Deterioration in clinical symptoms relate to the calcium concentration, which, in turn, 
is to a certain degree related to the 25OHD concentration [14]. As per the debate relating 
to adequate 25OHD concentrations, there is also debate regarding optimal concentrations. 
Concentrations above 250 nmol l–1 are considered excessive, with concentrations above 
375 nmol l–1 (150 µg l–1) being associated with toxicity (Table 1) [14]. Vitamin D treatment 
appears to be safe at doses of up to 10 000 IU day–1, delivering 25OHD concentrations 
below levels associated with toxicity [14,15]. Indeed, others have shown that an average 
daily intake of 15 000 IU day–1 and plasma 25OHD concentrations up to 300 nmol l–1 are 
not associated with deranged calcium or phosphate metabolism or toxicity [16]. However, 
with the increasing use of vitamin D treatments, there are increasing reports of vitamin D 
toxicity in the literature which appear to relate to manufacturing errors, prescribing errors 
and increasing use of supplemental highdose products [17].
It is therefore of substantial public health importance to highlight both the potential 
consequences of vitamin D toxicity and the common underlying causes. In the present 
review, we evaluate vitamin D toxicity and explore its causes for recurrent themes. We 
have classified doses higher than 4000 IU as ‘high dose’, and those higher than 100 000 
as ‘mega dose’.
METHODS
We searched Medline for relevant articles published between January 1945 and August 
2017. We used various combinations of the following terms: ‘hypervitaminosis D’, ‘vitamin 
D’, ‘toxicity’, ‘toxic’ and ‘iatrogenic’. Additional publications were sourced from references 
in individual articles. Relevant articles were selected after reading through all titles and 
abstracts, and full texts were obtained if the information contained in the title or abstract 
was insufficient to exclude the study.
We selected studies for review if they indicated that a patient had received an excessive 
dose of vitamin D or had complications related to high vitamin D levels as a result of 
supplementation. The consequences of the vitamin D toxicity and the apparent causes 
behind its occurrence were also examined. As the nature of the research in this area has 
been predominantly case reports and series, we did not make a formal assessment of the 
quality of the research or undertake a formal systematic review with metaanalysis and 
GRADE assessment of the quality of evidence.
Our search criteria, used by both authors, identified 437 publications, of which 109 were 
potentially relevant based on examining the title and abstract, and 62 were included in the 
final analysis. It is noteworthy that the earliest identified papers regarding the causes and 
complications of excess vitamin D supplementation were first published over 50 years ago
[18,19].
RESULTS
Summary
All references used in the present work were identified in a Medline search; no additional 
references were found by searching the reference lists in the identified papers. In our 
review, three main themes emerged, with vitamin D excess and toxicity arising from errors 
in formulation or fortification (the most common), inappropriate prescribing or dispensing, 
and errors in administration. Of the 62 papers included in the final analysis, 44 were 
relevant (the rest being reviews or explanations of the physiology of vitamin D). Twenty 
papers related to fortification errors; these occurred globally, with events occurring in North 
America, South America, India and Australia. There were 17 reports of inappropriate 
prescribing or dispensing, with nine of these coming from India, the largest of which 
comprised a case series of 62 patients, and the others from the USA, Canada and the UK. 
Of the 17 reports of inappropriate prescribing, the majority 15 were due to errors in 
prescribing. There were seven reports of errors in administration (including self
administration); the largest analysis, from the UK, comprised 372 cases of excess vitamin 
D levels (>220 nmol l–1), with 349 of these not under direct medical supervision. Other 
reports of errors in administration were from the USA, Netherlands, Japan and Brazil.
Publications for vitamin D had a 4.1 fold increase in annual frequency from 2001 to 2016, 
with the greatest increases after 2009 (Figure 1). Similarly, only five of the 20 reports of 
fortification errors, five of the 17 errors in prescribing or dispensing, and one of the seven 
reports of administration errors were published before 2010. Problems appeared to be 
most common in paediatric and elderly populations.
Causes of vitamin D toxicity
Formulation or fortification errors
With the early and widespread fortification of foodstuffs with vitamin D, there were 
numerous reports of vitamin D intoxication [20], suggesting errors in food manufacturing. 
Indeed, other studies of fortified foodstuffs revealed substantial manufacturing errors, 
confirming marked differences between the stated and actual doses [21]. Overfortification 
of vitamin D in milk resulted in hypervitaminosis D in the local population, leading to at 
least 56 cases; 41 required hospitalization and there were two deaths [22], reinforcing the 
need for careful ongoing production monitoring [23].
The problem of accurate dosing of vitamin D is not just confined to food fortification, and is 
a particular issue when supplements are unlicensed. The manufacture of both 
ergocalciferol and cholecalciferol requires considerable pharmaceutical expertise if 
inaccurate dosing is to be avoided. Thus, many countries have agencies which oversee 
the production and safety of pharmaceutical products; in the UK, this role is performed by 
the Medicines and Healthcare Products Regulatory Authority (MHRA).
A New Zealand study of 14 (12 unlicensed and two licensed) vitamin D3 formulations 
revealed that only eight were within 10% of the stated dose [24]. Similarly, a US study [25] 
demonstrated that, of the 15 vitamin D3 preparations analysed, there was substantial 
variation compared with the stated dose, both in pills from the same bottle (52–136% of 
expected dose) and between separate preparations (9–140% of stated dose). Only one
third of the pills analysed were within 10% of the stated dose. Of these, the licensed 
products revealed the greatest accuracy and least variation with the stated dose. Similarly, 
an Indian study revealed that, of 14 commonly used preparations, only four were found to 
be within the accepted 90–125% of stated dose, defined by the Indian Pharmacopeia [26]. 
Furthermore, US studies on the fortification of foods with vitamin D have also revealed 
wide variations from the stated dose as nutritional products are not as well regulated as 
medicines.
While the problematic manufacture of vitamin D products may at first appear trivial, such 
inaccuracies appear to be responsible for the majority of cases of vitamin D toxicity 
reported in the literature (Table 2). Koutkia et al. [27] reported severe hypercalcaemia and 
renal failure due to vitamin D toxicity in a subject taking vitamin D3 at a stated dose of 
2000 IU day–1, yet analysis of the medication revealed actual doses of up to 2.6 million IU 
day–1. Another US study reported on a woman with vitamin D toxicity associated with the 
use of a vitamin D supplement containing 188 000 IU of cholecalciferol rather than the 
stated dose of 400 IU [28]. Benemei et al. [29] reported three cases of vitamin D 
intoxication with severe hypercalcaemia, where the patients had been treated with a 
vitamin D formulation with a stated dose of 600 IU, whereas, in fact, the actual content was 
52 800 IU. Similar manufacturing errors, producing serious toxicity and hospitalization, has 
also been reported in children [30-33]. Seven paediatric cases of hypercalcaemia due to 
vitamin D intoxication were reported in association with a fish oil supplement, where the 
stated dose was roughly 4000 times less than the actual dose [31]; in one of these cases, 
an infant in whom the stated daily dose was 2000 IU day–1 was actually taking 6000 IU 
day–1 [30]. Toxicity associated with inaccurately manufactured and labelled vitamin D 
supplements is a globally reported problem [32], [34-43]. To our knowledge, such errant 
labelling has not been reported in conjunction with licensed formulations.
Inappropriate prescribing or dispensing
Highdose formulations are a particular cause for concern. Stoss therapy for vitamin D 
deficiency, with high doses of vitamin D over relatively short periods, progressing to much 
lower maintenance doses, has encouraged the development of highdose vitamin D 
therapies (60 000 IU and above). With evidence indicating that doses of 10 000 IU day–1 or 
below do not cause vitamin D toxicity [15], and that such doses are effective in resolving 
vitamin D deficiency [38], it may seem that having superstrength doses might expose 
subjects to unnecessary risk through either errant prescribing or inappropriate self
medication. Indeed, vitamin D toxicity is described in association both with highdose over
thecounter supplements [39] being taken too frequently and prescribed in error by the 
physician [40,44,45], and being filled incorrectly by the pharmacist – for example, a 
50 000 IU prescription provided daily instead of weekly [46]. With regard to the former, a 
case report of a patient using 60 000 IU of supplemental vitamin D two to three times a 
week, Chatterjee et al. [39] noted vitamin D toxicity to be associated with reversible 
parkinsonism. Similarly, doses of 88 000 IU day–1 were reported to be associated with 
toxicity in a patient selfmedicating for multiple sclerosis [16]. Worryingly, there have been 
a number of case reports on the mistaken administration of high doses of vitamin D to 
children by parents, resulting in hospitalization with severe toxicity [47,48]. Vitamin D 
toxicity following excessive replacement by the medical community with prolonged high 
doses of vitamin D has also been reported [44,45,49-54]. All of these patients had been 
treated injudiciously with high doses of parenteral vitamin D, and all had been receiving 
vitamin D treatment under medical supervision. These reports of toxicity associated with 
injudicious use of high doses of parenteral vitamin D preparations seem to be a particular, 
although not unique, problem of the Indian subcontinent [55]. Furthermore, in some cases 
these treatments were initiated for inappropriate reasons, such as failure to thrive [56]. 
Ziaie et al. [57] reported the case of an Iranian male who had been treated with 300 000 IU 
of parenteral vitamin D weekly presenting with severe and prolonged vitamin D toxicity.
In children with rickets, for whom a single parenteral megadose of vitamin D is considered 
effective and economical, substantially elevated 25OHD concentrations have been noted, 
exposing patients to the risk of toxicity [52,58]. Indeed, toxicity has been reported in an 
infant treated with highdose vitamin D while under medical supervision [59], and also in 
an infant treated with supplemental highdose vitamin D drops [60]. There is a clear risk of 
vitamin D toxicity arising in these patients as there are several different treatment 
regimens and monitoring schedules, compounded by a lack of agespecific guidance [1]. A 
recent French case series of nine children who presented with severe hypercalcaemia 
following a cumulative dose of 600 000 units also indicated the need to adhere to current 
recommended vitamin D doses [61]. There is also a case of megadoses of vitamin D being 
used inappropriately by an alternative health practitioner, resulting in patient harm [62].
While it might appear that prescribing errors account for a worryingly high number of cases 
of vitamin D toxicity, populationbased studies suggest that these represent a minority of 
such cases [63]. In a UK study of requests for commercially available direct blood spot 
analysis of 25OHD concentrations, 372 (2.5% of total) requests had concentrations above 
220 nmol l–1, with 28 of these having concentrations above 500 nmol l–1 [63]. Of the entire 
group with elevated 25OHD concentrations (>220 nmol l–1), only 6% were under direct 
medical supervision, and the majority (74%) obtained their vitamin D supplement directly 
over the internet [63]. As this was a blood spot analysis, the authors could not determine 
toxicity through measurement of calcium concentrations, although this, again, suggests 
that the public is being put at risk through the availability of highdose preparations. In fact, 
an earlier analysis of these data revealed that, of the respondents with 25OHD 
concentrations >220 nmol l–1 who were contacted, 55% indicated that they were taking 
doses of 10 000 IU day–1 or less. With studies revealing that toxicity does not occur with 
daily vitamin D doses up to 10 000 IU day–1 [15], these data suggest that, again, errant 
manufacturing may be exposing the public to risk [64]. Of the six subjects who had 25OHD 
concentrations above 550 nmol l–1, one was under medical supervision, taking high doses 
against medical advice, with the remaining five independently using high doses (11 000–
100 000 IU day–1) of vitamin D [63]. In a Spanish study, a similar figure of 1.86% of 
patients for whom requests for 25OHD concentrations were made were found to have 
hypervitaminosis D, as defined by 25OHD levels above 160 nmol l–1, of whom, 51 
(0.002%) had hypercalcaemia [65]. An Irish study [66] revealed a prevalence of 4.8% of 
raised vitamin D 25OHD levels, although an elevated result was considered as 
25OHDlevels >125 nmol l–1, as per Institute of Medicine (IOM) criteria. All of these patients 
appeared to be under medical supervision.
Inappropriate administration of vitamin D
A single dose of 2 000 000 IU of vitamin D was given in error to two nursing home 
residents [67], leading to a call to replace multiple use bottles with smaller singleunit dose 
formulations. At the other extreme of age, most premature infant formulas have high 
vitamin D levels, which, while safe for short durations, if prolonged feeding is undertaken 
can result in excessive levels of vitamin D (>100 nmol l–1) [68]. Careful monitoring in these 
patients is therefore essential. Errors in maternal vitamin D replacement can also result in 
substantial hypercalcaemia in the offspring. In one study, an exclusively breastfed infant 
required emergency admission [69]. The mother was on a vitamin D prescription of 1 ml 
(400 IU per 1 ml daily); however, the concentration of the vitamin D supplement she had 
purchased online was 400 IU per drop, resulting in a 30fold higher dose than intended 
(12 000 IU day–1), with excess vitamin D being present in her breast milk [69].
Toxic vitamin D levels can also arise from misuse and inappropriate administration. A 19
yearold male was admitted with acute kidney injury and hypercalcaemia, with a vitamin D 
level of 150 ng ml–1. He was using a parenteral formulation of vitamins A, D and E that 
was restricted for veterinary use, containing 20 000 000 IU of vitamin A, 5 000 000 IU of 
vitamin D3 and 6800 IU of vitamin E per 100 ml. He was using the preparation as a ‘filler’ 
to enhance his muscle definition, rather than for any nutritional benefit [70]. Other lifestyle 
causes of excess vitamin D should also be considered, including excess use of tanning 
beds [71].
DISCUSSION
Vitamin D sufficiency is a key determinant of health, and supplementation is commonly 
required. The substantial public health benefits of ensuring vitamin D sufficiency may, 
however, be partially offset by a minority of individuals who suffer from adverse outcomes 
owing to vitamin D toxicity. The fact that it is a vitamin and a frequently used nutritional 
supplement, may have led to considerable complacency regarding its potential for toxic 
effects. This, combined with the dramatic expansion in vitamin D interest arising, in part, 
from popular books extolling the virtues of highdose vitamin D [72], it is perhaps not 
surprising there has been such an increase in the number of cases of vitamin D toxicity.
The causes of vitamin D toxicity appear to be multiple, and include the use of unlicensed 
and poorly manufactured products. In addition, there is widespread availability and 
inappropriate use of highdose overthecounter supplements, and prescribing errors 
arising from the injudicious use of highdose supplements. Prescribers and dispensers 
need to appreciate the potential dangers to their patients and, wherever possible, mitigate 
against causing them harm. Standardizing replacement and monitoring regimes, and 
growing awareness among physicians of the potential risks of vitamin D toxicity, with 
acceptance of a therapeutic window, are clearly essential [73]. It is, however, surprising 
that vitamin D toxicity still occurs, through lack of clear guidance and regulation, despite 
awareness of this problem for over 50 years.
To our knowledge, this is the first comprehensive review of vitamin D toxicity. It highlights 
the pressing need for substantial improvements in the delivery of vitamin D products. 
However, there are key limitations; the nature of this topic has limited the literature 
predominantly to case reports and case series, and the evidence base is therefore of only 
moderate quality. Nevertheless, we observed clear themes in the causes of vitamin D 
toxicity; furthermore, the majority of cases appeared to have been easily preventable.
CONCLUSION
In summary, vitamin D toxicity remains an ongoing issue and its incidence is likely to rise, 
owing to both increasing interest and the widespread prescribing of vitamin D. The 
patients at greatest risk are likely to be at the extremes of age. Simple legislation to ensure 
the quality of all vitamin D products, together with limited and restricted use of very high
dose formulations, may substantially reduce future public harm, as the majority of cases 
appear, in retrospect, to have been easily preventable.
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